1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Piramal Enterprises Limited

Piramal Enterprises Limited

PEL.NS
Piramal Enterprises LimitedIN flagNational Stock Exchange of India
1,124.20
INR
+8.80
- -
254.86BMarket Cap
Piramal Enterprises Limited
PEL.NS
(National Stock Exchange of India)

Recent

price

1,124.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
156.44
72.12
121.31
196.63
251.48
286.63
355.29
475.39
567.82
581.3
615.32
538.56
322.8
340.38
417.7
419.61
440.36
Revenue per Share
20.8
555.37
6.41
-12.78
-28.2
160.29
50.89
70.55
275.06
72.2
1.14
56.19
80.7
417.68
-72.82
21.55
25.71
Basic EPS, GAAP
6.3
-205.32
-52.88
-111.36
-110.5
-150.99
-430.59
-688.94
-901.48
-605.45
334.28
129.44
314.09
44.65
-50.8
-371.4
- -
Free Cash Flow per Basic Share
4.43
5.67
11.54
16.99
16.9
50.69
36.04
0.2
19.33
22.06
26.41
13.32
33.47
33
32
10
- -
Dividend per Share
26.31
254.14
305.12
265.8
178.03
311.42
325.08
388.66
625.39
560.5
572.05
525.17
687.46
657.32
555.33
581.6
- -
Book Value per Share
36.46
485.02
593.82
332.1
220.9
326.73
376.32
351.6
947.42
895.62
1,258.22
1,318.6
1,349.78
1,284.52
1,139.07
1,191.62
- -
Tangible Book Value per Share
232
232
174
178
178
178
178
177
186
203
211
237
238
239
231
225
226
Basic Weighted Avg Shares
36,245
16,731
21,098
34,959
44,712
50,962
63,168
84,380
105,726
118,124
129,692
127,708
76,921
81,235
96,574
94,504
99,384
Sales/Revenue/Turnover
19.05
-3.66
-5.93
6.49
9.07
12.28
22.73
37.03
44.32
55.58
60.07
54.25
65.63
46.27
43.95
42.5
46.89
Operating Margin (%)
1,426
959
1,293
2,096
2,469
2,899
2,555
3,818
4,778
5,202
6,590
5,609
6,658
1,229
1,686
2,137
2,198
Depreciation Expense
4,819
128,834
1,115
-2,273
-5,014
28,500
9,047
12,523
51,215
14,671
240
13,323
19,231
99,686
-16,835
4,854
5,803
Net Income, GAAP
3.61
22.41
4.66
- -
- -
11.36
5.19
17.41
- -
33.53
139.32
59.12
19.64
- -
- -
24.72
16.86
Effective Tax Rate (%)
13.3
770.04
5.28
-6.5
-11.21
55.92
14.32
14.84
48.44
12.42
0.19
10.43
25
122.71
-17.43
5.14
5.84
Profit Margin (%)
8,911
49,614
-8,746
-40,638
-51,184
-3,298
-58,873
-97,989
-99,131
-188,226
-75,599
65,202
555,718
118,479
55,416
40,403
- -
Working Capital
12,950
6,566
6,482
11,610
26,796
37,875
74,812
145,015
242,247
270,355
204,504
282,372
554,510
337,358
385,379
439,535
- -
LT Debt
16,849
118,422
112,524
107,354
93,211
117,650
129,485
148,958
265,744
272,333
305,716
351,390
368,369
310,591
265,570
270,959
- -
Total Equity
23.59
-0.61
-0.92
- -
- -
2.93
5.64
6.92
- -
5.66
-3.91
3.82
4.36
- -
- -
3.48
- -
Return on Invested Capital (%)
35.79
303.63
2.92
- -
- -
25.43
10.36
9.77
- -
6.69
-3.23
5.44
6.08
- -
- -
3.75
31.17
Return on Capital (%)
92.61
396.1
1.99
-4.53
-12.71
65.5
15.99
19.76
55.24
12.74
0.2
10.87
13.34
62.17
-11.8
3.74
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
215,347
- -
LT Borrowings
- -
439,535
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
225
- -
Market Capitalization
248,745
222,434
258,233

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
275,485
- -
Cash, Cash Equivalents & STI
- -
97,615
- -
Accounts Receivable, Net
- -
59
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
235,082
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
215,347
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.99%
-1.68%
2.03%
Free Cash Flow
50.18%
80.72%
612.18%
Net Income, GAAP
577.09%
1,132.29%
-128.84%
Sales/Revenue/Turnover
8.54%
-3.79%
-2.14%
Total Cash Common Dividend
1,007.87%
6.49%
-69.57%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18,728
19,193
20,947
35,265
96,574
2025
20,374
22,145
23,104
28,880
94,504
2026
25,255
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21.32
2.03
-105.83
- -
-72.82
2025
8.08
7.23
1.71
- -
21.55
2026
12.22
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
32
2025
- -
- -
- -
- -
10
2026
- -
- -
- -
- -
- -
Similar Companies
Shinpoong Pharmaceutical Co., Ltd. (019170.KS)
RAMM Pharma Corp. (RAMMF)
Glenmark Pharmaceuticals Limited (GLENMARK.BO)
Aarti Pharmalabs Limited (AARTIPHARM.BO)
Rapid Nutrition PLC (ALRPD.PA)
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK)
Business
Piramal Enterprises Limited (PEL.NS) operates as a diversified non-banking financial company registered with the Reserve Bank of India, focusing on retail lending with assets under management of approximately $10 billion across 25 states and 269 cities in India. The company provides a range of financial products including home loans, home construction finance, business loans, personal loans, secured business loans, used car loans, small business loans, loans against property, and mutual fund distribution services; it leverages advanced technologies such as artificial intelligence and analytics to deliver these offerings. Founded in 1988 and headquartered in Mumbai, India, PEL serves individual and corporate customers primarily in the Indian market through organic expansion and strategic acquisitions. In recent developments, PEL advances toward a merger with its subsidiary Piramal Finance Limited, with National Company Law Tribunal approval secured and completion targeted for the third quarter of fiscal 2026, alongside prior Reserve Bank of India nod; it announced a co-lending partnership with RBL Bank in January 2025 and unveiled the 'Parakh' credit assessment tool through Piramal Finance in the same month. These initiatives support robust growth, including 12% year-over-year assets under management increase to ₹74,692 crore reported in the second quarter of fiscal 2025. PEL forms part of the broader Piramal Group, which maintains interests in healthcare and real estate alongside financial services.